Abstract: To provide a release film not to contaminate a mold or a molded article. The present invention provides a release film comprising, an oligomer bleeding prevention layer formed of an acrylic resin or a siloxane resin and laminated on a first face of a base layer that is formed of a polyethylene terephthalate resin; a surface layer formed of a fluororesin and laminated on the oligomer bleeding prevention layer; and a surface layer formed of a fluororesin and laminated on a second face of the base layer, or an oligomer bleeding prevention layer formed of an acrylic resin or a siloxane resin and laminated on a second face of the base layer, and a surface layer formed of a fluororesin and laminated on the oligomer bleeding prevention layer that is laminated on the second face.

Abstract: A method of producing a solder material is provided. The method includes mixing a flux containing a solvent, a rosin-based resin, and an activator, with aggregated cellulose. The aggregated cellulose includes massive cellulose in which fibrous cellulose having a length of from 1 ?m or more to less than 1 mm, and fibrous cellulose having a length of from 1 nm or more to less than 1 ?m. The resulting mixture is mixed with a solder alloy to produce a solder material.

Abstract: Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.

Abstract: An oligonucleotide that inhibits the binding of a serine/arginine-rich protein 30c (SRp30c) to a pre-mRNA of a glucocorticoid receptor gene in vivo.

Abstract: Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.

Abstract: An oligonucleotide that inhibits the binding of a serine/arginine-rich protein 30c (SRp30c) to a pre-mRNA of a glucocorticoid receptor gene in vivo.

Abstract: A connector has a housing (20) with a plurality of cavities (21) for accommodating terminal fittings (10). A resiliently deflectable lock (37) is provided at the bottom surface of each cavity (21). Terminal fittings (10) are inserted into the cavities (21). Front and rear stabilizers (13A, 13B) project down from each terminal fitting (10) and are separate by an engaging recess (17) into which a portion (38) of the respective lock (37) is inserted for locking the terminal fitting (10) in the cavity (21).

Abstract: A connector has a housing (20) with a plurality of cavities (21) for accommodating terminal fittings (10). A resiliently deflectable lock (37) is provided at the bottom surface of each cavity (21). Terminal fittings (10) are inserted into the cavities (21). Front and rear stabilizers (13A, 13B) project down from each terminal fitting (10) and are separate by an engaging recess (17) into which a portion (38) of the respective lock (37) is inserted for locking the terminal fitting (10) in the cavity (21).